BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Hamas hands over another body in the Gaza Strip - 2‘Inoculation’ helps people spot political deepfakes, study finds
- 3Bitcoin momentum builds in Abu Dhabi as global interest surges
- 4France's Senate backs ban on social media platforms for under-15s
- 5Some super-smart dogs can pick up new words just by eavesdropping
- 6 Popular Ladies' Aromas On the planet
- Building an Individual Brand: Illustrations from Forces to be reckoned with
- 10 Demonstrated Tips to Dominate Video Altering on Your Cell phone in 2023
- Turning into a Sharp Financial backer: Individual budget Wins
- Administrative building in Sharjah region targeted by Iranian drone, UAE authorities announce
- Vote in favor of Your #1 sort of pie
- Public Parks in the USA
- Meet the Stars of the Feline World: Well known Pet Feline Varieties
- Moldova says Russian drones violated airspace
